Novo Nordisk shares fall as Wegovy pill sales miss forecasts
The short version
Novo Nordisk raised its annual outlook for obesity and diabetes drugs. Shares in the Danish company fell after sales of its Wegovy weight-loss pill did not meet forecasts.
Novo Nordisk raised its full-year guidance for obesity and diabetes drugs.2,1 The company raised its forecasts for the second time in 2026.1 Novo Nordisk's US shares fell after sales of the Wegovy weight-loss pill did not meet analyst expectations.1
The Wegovy pill is a weight-loss medication developed by Novo Nordisk.2,1 Analysts had expected higher sales of the Wegovy pill.1
Why it matters
- More on
- Stocks
This account was written from the 2 reports listed below, filed by 2 independent outlets, and checked against them line by line. It is not a copy of any one of them. Spotted an error? Tell us.
Comments
0Comments are screened automatically. Disagreement is welcome; abuse and spam are not.
Loading…
Related
Novo Nordisk loses GLP-1 drug lead to Eli Lilly
Danish pharmaceutical giant Novo Nordisk saw its dominance in GLP-1 weight-loss drugs challenged by U.S. rival Eli Lilly after pioneering breakthrough treatments.
SK Hynix shares rise on buyback speculation
SK Hynix shares advanced after overnight gains in US chipmakers and reports of a potential shareholder return plan.
Alexander Hatley from Spring, Texas, USA / CC BY 2.0SpaceX revenue jumps 92% in first earnings after IPO
SpaceX reported $7.8 billion in quarterly revenue, a 92% increase, but posted a $541 million net loss in its first earnings report since going public in June.
FDV / CC BY-SA 4.0AstraZeneca shares drop after $400bn Bristol-Myers deal talks
A potential $400bn merger between AstraZeneca and Bristol-Myers Squibb would create the world's fourth-largest drugmaker but faces investor skepticism.